Idiopathic pulmonary fibrosis is a progressive disease, with a high mortality within the first 3-
5 years from diagnosis and a poor quality of life mainly because of the burden of symptoms …

For patients with idiopathic pulmonary fibrosis (IPF), prognosis is extremely poor and
treatment options are limited. An improved understanding of the experiences and …

Background Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease with a survival
of only three to five years from the time of diagnosis. Due to a paucity of studies, large gaps …

IPF is a devastating disease. Because there is no cure, an improved understanding of how
this disease affects patients' lives is needed. Rigorously developed and carefully …

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung
disease. The combination of poor prognosis, uncertainty of disease course and severe …

BACKGROUND: Patients were recruited from the Dorothy P. and Richard P. Simmons
Center for Interstitial Lung Disease, located within the University of Pittsburgh Medical …

Background Limited data are available on the association between clinically measured
disease severity markers and quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). The …

Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that
causes deterioration of the structure of the lung parenchyma, resulting in a severe and …

Despite several advances in treatment, idiopathic pulmonary fibrosis (IPF) remains a
progressive, symptomatic, and terminal disease in patients not suitable for lung …

Patient-reported outcomes (PROs) include questionnaires or surveys that ask patients for
their perceptions about things like symptoms they are experiencing or quality of life. For …